PF-562271 is a potent inhibitor of focal adhesion kinase (FAK) and proline-rich tyrosine kinase 2 (Pyk2), enzymes involved in cell adhesion, migration, and survival. It is primarily used in research settings to study tumor growth and metastasis, as FAK signaling plays a key role in cancer progression. The compound has demonstrated activity in reducing cancer cell proliferation and invasion in various preclinical models, particularly in solid tumors such as ovarian, breast, and pancreatic cancers. In addition to oncology research, PF-562271 is used to investigate cellular processes related to cytoskeletal dynamics and integrin signaling. Its ability to block FAK autophosphorylation makes it a valuable tool for understanding the role of FAK in angiogenesis and tumor microenvironment interactions. Due to its pharmacokinetic profile, it has also been employed in in vivo studies to assess the therapeutic potential of FAK inhibition, including combination therapies with chemotherapy or targeted agents.